BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 1322566)

  • 21. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
    Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene analysis of Epstein-Barr virus-associated lymphomas in Hu-Pbl/SCID chimeras.
    Gan R; Xie X; He J; Liu X; Hong L; Tang Y; Liu F; Xie H
    Tumori; 2010; 96(3):465-72. PubMed ID: 20845810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
    Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
    J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans.
    Purtilo DT; Falk K; Pirruccello SJ; Nakamine H; Kleveland K; Davis JR; Okano M; Taguchi Y; Sanger WG; Beisel KW
    Int J Cancer; 1991 Feb; 47(4):510-7. PubMed ID: 1847355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency.
    Mosier DE; Gulizia RJ; Baird SM; Spector S; Spector D; Kipps TJ; Fox RI; Carson DA; Cooper N; Richman DD
    Curr Top Microbiol Immunol; 1989; 152():195-9. PubMed ID: 2553338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
    Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
    Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
    Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
    J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10.
    Baiocchi RA; Ross ME; Tan JC; Chou CC; Sullivan L; Haldar S; Monne M; Seiden MV; Narula SK; Sklar J
    Blood; 1995 Feb; 85(4):1063-74. PubMed ID: 7849294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Epstein-Barr virus and interleukin 6 in the development of lymphomas of human origin in SCID mice engrafted with human tonsillar mononuclear cells.
    Nadal D; Albini B; Schläpfer E; Bernstein JM; Ogra PL
    J Gen Virol; 1992 Jan; 73 ( Pt 1)():113-21. PubMed ID: 1309857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice.
    Cannon MJ; Pisa P; Fox RI; Cooper NR
    J Clin Invest; 1990 Apr; 85(4):1333-7. PubMed ID: 2156900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice.
    Okano M; Taguchi Y; Nakamine H; Pirruccello SJ; Davis JR; Beisel KW; Kleveland KL; Sanger WG; Fordyce RR; Purtilo DT
    Am J Pathol; 1990 Sep; 137(3):517-22. PubMed ID: 1975985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus induced lymphoproliferative tumors in severe combined immunodeficient mice are oligoclonal.
    Pisa P; Cannon MJ; Pisa EK; Cooper NR; Fox RI
    Blood; 1992 Jan; 79(1):173-9. PubMed ID: 1309425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
    Feng WH; Hong G; Delecluse HJ; Kenney SC
    J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.
    Murphy WJ; Funakoshi S; Beckwith M; Rushing SE; Conley DK; Armitage RJ; Fanslow WC; Rager HC; Taub DD; Ruscetti FW
    Blood; 1995 Sep; 86(5):1946-53. PubMed ID: 7544649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies.
    Williams SS; Umemoto T; Kida H; Repasky EA; Bankert RB
    J Immunol; 1992 Oct; 149(8):2830-6. PubMed ID: 1401915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease.
    Fuzzati-Armentero MT; Duchosal MA
    Histol Histopathol; 1998 Jan; 13(1):155-68. PubMed ID: 9476646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.